Manejo de la inmunosupresión en pacientes trasplantados de riñón con COVID19. Estudio multicéntrico nacional derivado del registro COVID de la Sociedad Española de Nefrología

Introduction: SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient`s clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated.Objectives: Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis.Material and methods: Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis.Results: renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years. The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased. Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7 +/- 0.8, 2.1 +/- 1.2 and 1.8 +/- 1 mg/dl respectively (p < 0.001). 56.9% of the patients (N = 350) were monitored for anti-HLA antibodies. 94% (N = 329) had no anti-HLA changes, while 6% (N = 21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N = 9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant.Conclusions: The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis

Extinction risk of Mesoamerican crop wild relatives

Ensuring food security is one of the world's most critical issues as agricultural systems are already being impacted by global change. Crop wild relatives (CWR)—wild plants related to crops—possess genetic variability that can help adapt agriculture to a changing environment and sustainably increase crop yields to meet the food security challenge. Here we report the results of an extinction risk assessment of 224 wild relatives of some of the world's most important crops (i.e. chilli pepper, maize, common bean, avocado, cotton, potato, squash, vanilla and husk tomato) in Mesoamerica—an area of global significance as a centre of crop origin, domestication and of high CWR diversity. We show that 35% of the selected CWR taxa are threatened with extinction according to The International Union for Conservation of Nature (IUCN) Red List demonstrates that these valuable genetic resources are under high anthropogenic threat. The dominant threat processes are land use change for agriculture and farming, invasive and other problematic species (e.g. pests, genetically modified organisms) and use of biological resources, including overcollection and logging. The most significant drivers of extinction relate to smallholder agriculture—given its high incidence and ongoing shifts from traditional agriculture to modern practices (e.g. use of herbicides)—smallholder ranching and housing and urban development and introduced genetic material. There is an urgent need to increase knowledge and research around different aspects of CWR. Policies that support in situ and ex situ conservation of CWR and promote sustainable agriculture are pivotal to secure these resources for the benefit of current and future generations

Neuropatía óptica hereditaria de Leber por mutación G11778A del ADN mitocondrial. Manejo de un caso

La neuropatía óptica hereditaria de Leber es una enfermedad genética mitocondrial que típicamente produce ceguera bilateral en adultos jóvenes varones. Además de la mutación del ADN mitocondrial son necesarios otros factores genéticos y ambientales para el desarrollo de la enfermedad. En la actualidad no existe un tratamiento eficaz para la neuropatía óptica hereditaria de Leber, pero el consejo genético en portadores asintomáticos es importante. Presentamos el caso clínico de un paciente de 23 años de edad que refiere pérdida de agudeza visual central aguda unilateral que se convierte en bilateral en semanas. La exploración del fondo de ojo (tortuosidad vascular peripapilar, telangiectasias e hiperemia papilar), la angiografía con fluoresceína (con ausencia de exudación) y el engrosamiento de la capa de fibras nerviosas nos hacen sospechar la enfermedad. El test genético molecular confirma la neuropatía óptica hereditaria de Leber al encontrar la mutación G11778A en homoplasmia. A pesar del tratamiento con idebenona y suplementos vitamínicos la enfermedad evoluciona a atrofia papilar bilateral. El futuro parece estar en la terapia génica, actualmente en investigación

Effect of exposure of the oral cavity to various aromatized wine matrices on salivary parameters. Relationship with the changes in aroma during wine oral processing

Póster presentado al 16th Weurman Flavour Research Symposium, celebrado on-line del 4 al 6 de mayo ce 2021.Peer reviewe

Influence of metabolic syndrome on post-stroke outcome, angiogenesis and vascular function in old rats determined by dynamic contrast enhanced MRI

This work was supported by grants from Instituto de Salud Carlos III and cofinanced by the European Development Regional Fund “A Way to Achieve Europe” (PI17/01601 and RETICS RD16/0019/0009; I.L.), from Regional Madrid Government B2017/BMD-3688 (I.L.); from Spanish Ministry of Economy and Competitiveness SAF2015-68632-R (M.A.M.); from PICATA Project (Campus of international excellence of Moncloa; J.M.P.) and from M+Vision-COFUND Project (J.M.P.) (RTI2018-098682-B-I00 (MCIU/AEI/FEDER, EU) funded by the Spanish Ministry of Science and Innovation (MJLC).Stroke affects primarily aged and co-morbid people, aspects not properly considered to date. Since angiogenesis/vasculogenesis are key processes for stroke recovery, we purposed to determine how different co-morbidities affect the outcome and angiogenesis/vasculogenesis, using a rodent model of metabolic syndrome, and by dynamic enhanced-contrast imaging (DCE-MRI) to assess its non-invasive potential to determine these processes. Twenty/twenty-two month-old corpulent (JCR:LA-Cp/Cp), a model of metabolic syndrome and lean rats were used. After inducing the experimental ischemia by transient MCAO, angiogenesis was analyzed by histology, vasculogenesis by determination of endothelial progenitor cells in peripheral blood by flow cytometry and evaluating their pro-angiogenic properties in culture and the vascular function by DCE-MRI at 3, 7 and 28 days after tMCAO. Our results show an increased infarct volume, BBB damage and an impaired outcome in corpulent rats compared with their lean counterparts. Corpulent rats also displayed worse post-stroke angiogenesis/vasculogenesis, outcome that translated in an impaired vascular function determined by DCE-MRI. These data confirm that outcome and angiogenesis/vasculogenesis induced by stroke in old rats are negatively affected by the co-morbidities present in the corpulent genotype and also that DCE-MRI might be a technique useful for the non-invasive evaluation of vascular function and angiogenesis processes.Depto. de Bioquímica y Biología MolecularFac. de Ciencias BiológicasTRUEpu

La Libreta

Comunicación presentada en las Jornadas sobre Investigación e Innovación en la Educación Física escolar celebradas en el CEP de La Laguna, del 2 al 5 de junio de 2010Se presenta una actividad que trata de lograr que el alumnado tome decisiones en la preparación y organización de las tareas de clase de Educación Física. Se ha utilizado el “Grupo Estrella” como estrategia metodológica para favorecer la autonomía del alumnado. Del análisis de los resultados se desprende que una docencia donde se le deje tomar responsabilidades a los alumnos y alumnas proporciona satisfacción respecto al área, no obstante, la percepción del alumnado es que se pierde más tiempo y se aprende menos. La intervención docente debería ir encaminada a solventar estas percepciones.ES

Propuesta metodológica para la enseñanza de la Lucha Canaria en la educación básica

Se presenta una propuesta metodológica para introducir la enseñanza de la Lucha Canaria en los currículos de Educación Física, en las etapas de Educación Infantil, Primaria, Secundaria y Bachillerato, describiendo la relación entre los elementos prescriptivos y los contenidos propios del deporte más identificativo de las Islas Canarias. Se ha adaptado esta propuesta a las nuevas corrientes metodológicas, para el desarrollo de las capacidades básicas del alumnado, incorporándose las investigaciones desarrolladas en el ámbito universitario de la Comunidad, así como la literatura y otras publicaciones relacionadas.ES

Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology COVID registry Manejo de la inmunosupresión en pacientes trasplantados de riñón con COVID19. Estudio multicéntrico nacional derivado del registro COVID de la Sociedad Espa˜nola deNefrología

SARS CoV2 infection has had a major impact on renal transplant patients with a high mortality in the first months of the pandemic. Intentional reduction of immunosuppressive therapy has been postulated as one of the cornerstone in the management of the infection in the absence of targeted antiviral treatment. This has been modified according to the patient's clinical situation and its effect on renal function or anti-HLA antibodies in the medium term has not been evaluated. Evaluate the management of immunosuppressive therapy made during SARS-CoV2 infection, as well as renal function and anti-HLA antibodies in kidney transplant patients 6 months after COVID19 diagnosis. Retrospective, national multicentre, retrospective study (30 centres) of kidney transplant recipients with COVID19 from 01/02/20 to 31/12/20. Clinical variables were collected from medical records and included in an anonymised database. SPSS statistical software was used for data analysis. renal transplant recipients with COVID19 were included (62.6% male), with a mean age of 57.5 years. The predominant immunosuppressive treatment prior to COVID19 was triple therapy with prednisone, tacrolimus and mycophenolic acid (54.6%) followed by m-TOR inhibitor regimens (18.6%). After diagnosis of infection, mycophenolic acid was discontinued in 73.8% of patients, m-TOR inhibitor in 41.4%, tacrolimus in 10.5% and cyclosporin A in 10%. In turn, 26.9% received dexamethasone and 50.9% were started on or had their baseline prednisone dose increased. Mean creatinine before diagnosis of COVID19, at diagnosis and at 6 months was: 1.7 ± 0.8, 2.1 ± 1.2 and 1.8 ± 1 mg/dl respectively (p < 0.001). 56.9% of the patients (N = 350) were monitored for anti-HLA antibodies. 94% (N = 329) had no anti-HLA changes, while 6% (N = 21) had positive anti-HLA antibodies. Among the patients with donor-specific antibodies post-COVID19 (N = 9), 7 patients (3.1%) had one immunosuppressant discontinued (5 patients had mycophenolic acid and 2 had tacrolimus), 1 patient had both immunosuppressants discontinued (3.4%) and 1 patient had no change in immunosuppression (1.1%), these differences were not significant. The management of immunosuppressive therapy after diagnosis of COVID19 was primarily based on discontinuation of mycophenolic acid with very discrete reductions or discontinuations of calcineurin inhibitors. This immunosuppression management did not influence renal function or changes in anti-HLA antibodies 6 months after diagnosis